The biopharma industry seemed to escape the first of three hearings on the cost of prescription drugs held by the US Senate Committee on Health, Education, Labor and Pensions largely unscathed, as Democrats spent most of their time complaining about Senate Republican closed-door process for developing healthcare legislation and stayed away from in-depth discussions about Rx pricing.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?